Information  X 
Enter a valid email address

Synairgen hopes for positive data from Phase II asthma trial

By BFN News | 09:33 AM | Wednesday 01 February, 2012

The board of Synairgen says the positive data from the Phase II asthma trial in March 2012 will be a pivotal requirement for it to pursue the further development of inhaled IFN-beta with a licensing partner. Commenting, Simon Shaw, Chairman of Synairgen, said:"Such a partnership would be a significant commercial milestone for the Company and we have an ongoing dialogue with several potential development and commercialisation partners." Research and development expenditure for the year to end of December 2011 was: £1.8 million (year ended 30 June 2011: £2.9 million) Post-tax loss for the period: £2.0 million (year ended 30 June 2011: £3.2 million) Cash at 31 December 2011: £3.4 million (30 June 2011: £4.9 million) At 9:33am: (LON:SNG) Synairgen share price was 0p at 28.5p Story provided by

a d v e r t i s e m e n t